The investors in Cellexus, the Cell company which develops and commercialises novel single-use bioreactors and cell-based technologies for biopharmaceutical research and production, are pleased to announce the asset acquisition of Cellexus Biosystems Plc and formation a new management team to bring the Company’s exciting technologies and products to market.
Since acquiring the Cellexus Biosystems assets, which includes all of its Intellectual Property (IP), in April 2008 the Company has made significant design and operational improvements to the CellMaker bioreactor systems and intends to launch a range of new products, including the CellMaker Regular™ for culture of E. Coli and Pichia cells and the CellMaker PLUS™ for culture of all cells including mammalian and insect, over the coming months. The new systems are designed for improved performance to achieve higher yields of soluble protein using the single-use CellexusBag™. In addition the Company is developing a range of peripheral products, including those for sampling and oxygen generation, which will further facilitate system use and performance in an even broader range of conditions.
Mr Bob Cumming, the Cellexus General Manager, stated “We are delighted to have made this asset investment to form a new Company with proven IP operating in this exciting technology area with products offering significant improvements in cell culture technologies. We have formed an experienced Management Team and are committed to further product development, launching new improved products to meet our customers’ needs and to the future growth and success of the Company.
